An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Hodgkin's disease; Lymphoma
- Focus Adverse reactions
- Sponsors Millennium
- 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.